FRED HUTCHINSON CANCER RESEARCH CENTER;SEATTLE CHILDREN’S HOSPITAL DBA SEATTLE CHILDREN’S RESEARCH INSTITUTE
发明人:
Jensen, Michael,Riddell, Stanley,Hudecek, Michael
申请号：
NZ74537513
公开号：
NZ745375A
申请日:
2013.08.20
申请国别(地区):
NZ
年份:
2020
代理人:
摘要：
The present invention provides nucleic acids, vectors, host cells, methods and compositions for carrying out cellular immunotherapy, such as by adoptively transferring CD8+ T cells or combinations with CD4+ T cell, in which the T cells are genetically modified to express a chimeric receptor. In certain embodiments, the chimeric receptor is encoded by a nucleic acid comprising: (a) a polynucleotide encoding an antibody or antigen-binding fragment thereof that binds to a ROR1, wherein the antibody or antigen-binding fragment thereof binds to an epitope in the Kringle domain of ROR1； (b) a polynucleotide encoding a transmembrane domain； (c) a polynucleotide encoding a polypeptide spacer located between the antibody or antigen-binding fragment thereof and the transmembrane domain, wherein the polypeptide spacer is an immunoglobulin hinge-CH2-CH3 region； and (d) a polynucleotide encoding an intracellular signaling domain that comprises a CD3ζ signaling domain and a co stimulatory domain. Methods for preparing a host cell and pharmaceutical formulations produced by the methods, and methods of using the same, are also described.
